NCT07153705
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Not Yet Recruiting · Not specified · Beihua Kong · registry updated 2025-09-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.
Inclusion
- Women over 18 years old;
- Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;
- The expected survival period exceeds 6 months;
- CA125 ≤ 35 U/ml before initial treatment;
- Undergo surgery and adjuvant chemotherapy;
- The period between diagnosis and enrollment does not exceed 8 weeks;
Exclusion
- Have had other malignant tumors within the last five years;
- Have received any treatment for ovarian cancer;
- Benign ovarian mass;
- Non-primary ovarian tumors;
- Combined with other malignant tumors;
- Patients receiving neoadjuvant therapy;